Literature DB >> 12451431

Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells.

Tashinga E Bapiro1, Tommy B Andersson, Charlotta Otter, Julia A Hasler, Collen M Masimirembwa.   

Abstract

OBJECTIVE: To investigate the inductive effects of twenty-four antiparasitic drugs on cytochrome P450 (CYP) 1A1 and 1A2 enzyme activities.
METHODS: Human hepatoma (HepG2) cells were exposed to antiparasitic drugs for 24 h, and the ethoxyresorufin O-deethylase (EROD) activity, indicative of CYP1A enzyme activity, was measured fluorometrically. In addition, the CYP1A1 and CYP1A2 mRNA expression levels were determined by means of quantitative reverse-transcriptase polymerase chain reaction.
RESULTS: Quinine, albendazole and primaquine caused a dose-dependent increase in EROD activity of 5.5, 4.0 and 7.5-fold, at concentrations eliciting maximal induction, respectively. 2,3,7,8-tetrachlorodibenzo- p-dioxin, used as a positive control at a final concentration of 1.5 nM, caused a 30-fold increase in EROD activity. The induction of EROD activity was accompanied by an increase in CYP1A1 and CYP1A2 mRNA expression levels. Niclosamide, 4-chlorophenylbiguanide, dapsone, amodiaquine and desethylamodiaquine caused slight increases in EROD activity. No effect on CYP1A was observed for artemisinin, suramin, diethylcarbamazine, pyrimethamine, metrifonate, ivermectin, pyrantel artesunate, cycloguanil, atovaquone, melarsoprol, praziquantel, proguanil and dihydroartemisinin.
CONCLUSIONS: Quinine, albendazole and primaquine induce CYP1A1 and CYP1A2 at the transcriptional level. Considering the plasma concentrations (C(max)) achieved in vivo after administration of a therapeutic dose, induction by quinine and albendazole might be of clinical significance. The induction by primaquine, however, may not be of pharmacological or toxicological significance as concentrations at which it occurs are much higher than those attained in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12451431     DOI: 10.1007/s00228-002-0512-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity.

Authors:  Jiekun Xuan; Si Chen; Baitang Ning; William H Tolleson; Lei Guo
Journal:  Chem Biol Interact       Date:  2015-10-22       Impact factor: 5.192

2.  Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.

Authors:  Tashinga E Bapiro; Jane Sayi; Julia A Hasler; Mary Jande; Gerald Rimoy; Amos Masselle; Collen M Masimirembwa
Journal:  Eur J Clin Pharmacol       Date:  2005-10-29       Impact factor: 2.953

3.  A human liver microphysiology platform for investigating physiology, drug safety, and disease models.

Authors:  Lawrence A Vernetti; Nina Senutovitch; Robert Boltz; Richard DeBiasio; Tong Ying Shun; Albert Gough; D Lansing Taylor
Journal:  Exp Biol Med (Maywood)       Date:  2015-07-22

4.  Cryopreserved human hepatocytes as alternative in vitro model for cytochrome p450 induction studies.

Authors:  Martha Garcia; Joseph Rager; Qing Wang; Robert Strab; Ismael J Hidalgo; Albert Owen; Jibin Li
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Jul-Aug       Impact factor: 2.416

Review 5.  The search for endogenous activators of the aryl hydrocarbon receptor.

Authors:  Linh P Nguyen; Christopher A Bradfield
Journal:  Chem Res Toxicol       Date:  2007-12-13       Impact factor: 3.739

6.  Modulation of biotransformation systems and ABC transporters by benznidazole in rats.

Authors:  Virginia G Perdomo; Juan P Rigalli; Silvina S M Villanueva; María L Ruiz; Marcelo G Luquita; Claudia G Echenique; Viviana A Catania
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

7.  Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.

Authors:  Xue-Qing Li; Anders Björkman; Tommy B Andersson; Lars L Gustafsson; Collen M Masimirembwa
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

8.  Regulation of biotransformation systems and ABC transporters by benznidazole in HepG2 cells: involvement of pregnane X-receptor.

Authors:  Juan P Rigalli; Virginia G Perdomo; Marcelo G Luquita; Silvina S M Villanueva; Agostina Arias; Dirk Theile; Johanna Weiss; Aldo D Mottino; María L Ruiz; Viviana A Catania
Journal:  PLoS Negl Trop Dis       Date:  2012-12-13

9.  The effects of Mannheimia haemolytica and albendazole on marbofloxacin pharmacokinetics in lambs.

Authors:  Feray Altan; Duygu Neval Sayin Ipek; Orhan Corum; Simten Yesilmen Alp; Polat Ipek; Kamil Uney
Journal:  Trop Anim Health Prod       Date:  2019-06-23       Impact factor: 1.893

Review 10.  Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes.

Authors:  Florian Klomp; Christoph Wenzel; Marek Drozdzik; Stefan Oswald
Journal:  Pharmaceutics       Date:  2020-12-11       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.